Methods: This was a single-arm, non-randomized pilot study of carboplatin, taxane, and immune checkpoint inhibitor, pembrolizumab, followed by 12 months of maintenance pembrolizumab in patients with incompletely resected epithelial ovarian cancer (EOC). Results: A total of 29 patients...
Carboplatin/paclitaxel/pembrolizumab. Reactions Weekly 1923, 127 (2022). https://doi.org/10.1007/s40278-022-22990-2 Download citation Published10 September 2022 Issue DateSeptember 2022 DOIhttps://doi.org/10.1007/s40278-022-22990-2 Access this article Log in via an institution Buy article PDF...
Carboplatin, paclitaxel and pembrolizumab for the first line treatment of recurrent and/or metastatic head and neck squamous cell carcinoma. Journal for ImmunoTherapy of Cancer 8 (Suppl. 3): A118 abstr. 201, 2020. Available from: URL: http://doi.org/10.1136/jitc-2020-SITC2020.0201 [abstract]...
Selected KEYTRUDA® (pembrolizumab) Indications in the U.S. Endometrial Carcinoma KEYTRUDA, in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, is indicated for the treatment of adult patients with primary...
4University of Texas School of Public Health, Houston,TX, USA Introduction: Real-world comparative effectiveness, safety, and supportive care use of nab- paclitaxel plus carboplatin vs gemcitabine plus platinum were analyzed in patients with advanced or metastatic squamous cell non-small cell lung can...
Pembrolizumab and lenvatinib versus carboplatin and paclitaxel as first-line therapy for advanced or recurrent endometrial cancer: A Markov analysis 2021, Gynecologic Oncology Citation Excerpt : This finding aligns with the FDA-indication for the use of pembrolizumab in patients with MSI-high tumors. A...
Addition of pembrolizumab to carboplatin-paclitaxel/nab-paclitaxel improved overall survival (OS; hazard ratio [HR], 0.64; 95% CI, 0.49 to 0.85; P< .001) and progression-free survival (PFS; HR, 0.56; 95% CI, 0.45 to 0.70; P< .001) regardless of programmed death-ligand 1 (PD- L1) ...
The study KEYNOTE-407 investigated pembrolizumab in combination with carboplatin and either paclitaxel or nab-paclitaxel or chemotherapy alone in patients with stage IV squamous NSCLC who had not received previous systemic therapy for metastatic disease.4 The addition of pembrolizumab to the chemotherapy ...
Comparative efficacy of pembrolizumab with carboplatin and paclitaxel as first-line (1L) therapy in recurrent/metastatic head and neck squamous cell carcinoma ... D Zheng,A Mojebi,CM Black,... - 《Journal of Clinical Oncology》 被引量: 0发表: 2024年 Multicenter Phase 2 Trial of C is/Carbo...
Carboplatin/paclitaxel/pembrolizumab. Reactions Weekly 1845, 115 (2021). https://doi.org/10.1007/s40278-021-91998-8 Download citation Published06 March 2021 Issue DateMarch 2021 DOIhttps://doi.org/10.1007/s40278-021-91998-8 Access this article Log in via an institution Subscribe and save Spri...